SURVYR

RARE

Ultragenyx Pharmaceutical Inc.
$17.20
+$0.45 (2.69%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-64%-44%-25%-5%+15%Oct 2025Oct 2026Apr 202652w high $39.8952w low $12.73
RARESPY
Wall St. Highest PT $39.00 (+126.7%) Wall St. Avg PT $26.25 (+52.6%)
$13$23$33$43$53POC $24Hi $39Avg $26
Underwater Drawdown %Max DD -64.8%Current -52.9%
0.0%-64.8%
Relative Strength vs SPY-65.2% vs SPYUnderperforming
+86%0%-86%
1W
+$2.66 (18.29%)
1M
+$2.79 (19.36%)
3M
−$7.80 (31.20%)
6M
−$6.98 (28.87%)
YTD
−$5.80 (25.22%)
1Y
−$17.57 (50.53%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
20 analysts · mean score 2.14
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$17.20
Average target$26.25
+$9.05 (+52.6%) upsideaverage target vs current price
CurrentAverageMedian
Low$16.00
Median$26.25
High$39.00
12-month Wall Street target range
Recent analyst rating changes · 30
Initiated
2026-10-15 · UBS started covering RARE at Neutral
Reiterated
2026-09-21 · Evercore ISI Group reiterated In-Line on RARE
Reiterated
2026-09-21 · Barclays reiterated Overweight on RARE
Reiterated
2026-09-18 · Morgan Stanley reiterated Equal-Weight on RARE
Reiterated
2026-09-18 · Citigroup reiterated Buy on RARE
Reiterated
2026-09-18 · Canaccord Genuity reiterated Buy on RARE
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$1.5B
P/E (next 12 months, estimated)69.4
52-week range$12.73 – $39.89
Revenue growth (latest quarter vs a year ago)+28.1%
Dividend yieldNo dividend
Analyst consensusBuy (20)
Average analyst price target$26.25 (+53%)

What they do

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab).

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for RARE yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

RARE earningsNext report in 5 days
Next report · quarter Sep 2026
Tue Nov 3, 2026After the close
EPS consensus-$0.75 range -$1.25–$0.75
Revenue consensus$183.7M 17 analysts
Last 4 quarters · EPS vs estimate
Aug 4, 2026-$0.90est -$1.00+9.7%Above estimates
May 5, 2026-$1.54est -$1.46−5.7%Below estimates
Feb 12, 2026-$1.29est -$1.17−10.1%Below estimates
Nov 4, 2025-$1.81est -$1.21−49.7%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-23 23:42:49 ET
24-1125-0225-0525-0825-1126-0226-0526-08-1.810.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$214.0M+28.1%
2026-03-31$136.0M–
2025-12-31$207.3M–
2025-09-30$159.9M–
2025-06-30$167.0M–

News & catalysts

More news
Has The Story Under Krystal Biotech Stock Run Out?
Trefis · Oct 28
Broadcom upgraded, HubSpot downgraded: Wall Street's top analyst calls
The Fly · Oct 27
Rating changes
Initiated
2026-10-15 · UBS started covering RARE at Neutral
Reiterated
2026-09-21 · Evercore ISI Group reiterated In-Line on RARE
Reiterated
2026-09-21 · Barclays reiterated Overweight on RARE
Reiterated
2026-09-18 · Morgan Stanley reiterated Equal-Weight on RARE
Reiterated
2026-09-18 · Citigroup reiterated Buy on RARE
Reiterated
2026-09-18 · Canaccord Genuity reiterated Buy on RARE

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Horn Howard
Chief Financial Officer · 2026-10-15
Sell
$107.9K
Huizenga Theodore Alan
SVP, Chief Accounting Officer · 2026-09-15
Sell
$17.4K
Huizenga Theodore Alan
SVP, Chief Accounting Officer · 2026-09-03
Sell
$2.3K
Horn Howard
Chief Financial Officer · 2026-08-03
Sell
$117.0K
Parschauer Karah Herdman
EVP and Chief Legal Officer · 2026-08-03
Sell
$47.3K

Stats refreshed 2026-10-23 23:42:49 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026